{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Using both the incidence of dose limiting toxicities (first 28 days on therapy) as well as overall tolerability and toxicities observed beyond 28 days, the RD was chosen as 4 mg/kg of cabiralizumab + 3 mg/kg nivolumab every 2 weeks to be the dose used in the Phase 1b (dose expansion). No maximum tolerated dose was identified.","groups":[{"description":"Participants received escalating doses of cabiralizumab monotherapy or cabiralizumab in combination with nivolumab.","id":"OG000","title":"Overall Phase 1a Dose Escalation"}],"paramType":"NUMBER","populationDescription":"Participants enrolled in the dose escalation phase who received at least 2 doses of study drug during the 28-day evaluation interval or who discontinued study treatment for drug-related adverse events before receiving 2 doses of study drug were considered evaluable for DLT determination.","reportingStatus":"POSTED","timeFrame":"28 days","title":"Recommended Dose (RD) of Cabiralizumab in Combination With Nivolumab (Phase 1a)","type":"PRIMARY","unitOfMeasure":"mg/kg Q2W"}